pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›TYENNE
drug
save

TYENNE

Marketedupdated 3mo ago
by Fresenius Kabi USA LLC
Approved
community read0 votes

🐶 often sniffed alongside

top 5
  • tagApproval32 co-mentions · 8 sources
  • drugRNS-6016 co-mentions · 8 sources
  • drugACTEMRA16 co-mentions · 8 sources
  • companyFresenius Kabi USA LLC16 co-mentions · 8 sources
  • drugtocilizumab16 co-mentions · 8 sources

all catalysts(8)

approval · 8
Mar 5, 2024
approval
2y ago
TYENNE (TOCILIZUMAB-AAZG) — FDA approval
TYENNE
→
Sep 5, 2024
approval
2y ago
TYENNE (TOCILIZUMAB-AAZG) — FDA approval
TYENNE
→
Dec 3, 2024
approval
2y ago
TYENNE (TOCILIZUMAB-AAZG) — FDA approval
TYENNE
→
Dec 13, 2024
approval
2y ago
TYENNE (TOCILIZUMAB-AAZG) — FDA approval
TYENNE
→
Feb 28, 2025
approval
1y ago
TYENNE (TOCILIZUMAB-AAZG) — FDA approval
TYENNE
→
Mar 13, 2025
approval
1y ago
TYENNE (TOCILIZUMAB-AAZG) — FDA approval
TYENNE
→
May 12, 2025
approval
1y ago
TYENNE (TOCILIZUMAB-AAZG) — FDA approval
TYENNE
→
Jan 21, 2026
approval
7mo ago
TYENNE (TOCILIZUMAB-AAZG) — FDA approval
TYENNE
→
view all 8 catalysts →

Trials studying TYENNE

  • phase3A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)recruitingn=340

News(1)

  • Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles
    FOR IMMEDIATE RELEASE – August 10, 2026 – LAKE ZURICH, Ill.— Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (…
    fda_recalls · 8d ago
brand
TYENNE
generic
TOCILIZUMAB-AAZG
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 12m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?